PRESS RELEASE published on 07/09/2024 at 12:30, 1 year 10 months ago Immunic Appoints Jason Tardio as Chief Operating Officer and President Immunic appoints Jason Tardio as Chief Operating Officer and President, bringing extensive multiple sclerosis drug commercialization experience. Werner Gladdines promoted to Chief Development Officer Chief Operating Officer Multiple Sclerosis Immunic Jason Tardio Werner Gladdines
BRIEF published on 05/28/2024 at 12:35, 1 year 11 months ago Immunic to Participate in Industry and Scientific Conferences in June Biotechnology Investor Relations Conférences Chronic Diseases Scientific Engagement
BRIEF published on 05/28/2024 at 12:35, 1 year 11 months ago Immunic participera à des conférences industrielles et scientifiques en juin Biotechnologie Conférences Relations Avec Les Investisseurs Maladies Chroniques Engagement Scientifique
PRESS RELEASE published on 05/28/2024 at 12:30, 1 year 11 months ago Immunic to Participate in Industry and Scientific Conferences in June Immunic, Inc. (Nasdaq: IMUX) will participate in BIO International Convention 2024 and PCMG Assembly 2024 in June to present clinical pipeline of therapies for chronic inflammatory and autoimmune diseases Clinical Pipeline Immunic Inc IMUX BIO International Convention 2024 PCMG Assembly 2024
BRIEF published on 05/08/2024 at 12:35, 2 years ago Immunic, Inc. Announces Q1 2024 Financial Results and Corporate Updates Financial Strategy Immunic Inc Q1 2024 Financial Report Multiple Sclerosis Trials Celiac Disease Treatment
BRIEF published on 05/08/2024 at 12:35, 2 years ago Immunic, Inc. annonce ses résultats financiers du premier trimestre 2024 et des mises à jour sur l'entreprise Stratégie Financière Immunic Inc Rapport Financier Du Premier Trimestre 2024 Essais Sur La Sclérose En Plaques Traitement De La Maladie Coeliaque
PRESS RELEASE published on 05/08/2024 at 12:30, 2 years ago Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update Immunic, Inc. reports first quarter 2024 financial results, including capital increase and progress in MS and gastrointestinal disease therapies Financial Results Clinical Trials Immunic Inc. Gastrointestinal Disease MS Therapy
BRIEF published on 05/06/2024 at 12:35, 2 years ago Immunic AG Announces Participation in May Conferences for Investor and Scientific Communities Investor Conferences Clinical Trials Immunic AG Scientific Conferences Autoimmune Disease Treatments
BRIEF published on 05/06/2024 at 12:35, 2 years ago Immunic AG annonce sa participation aux conférences de mai destinées aux communautés d'investisseurs et scientifiques Essais Cliniques Conférences Investisseurs Immunic SA Conférences Scientifiques Traitements Des Maladies Auto-immunes
PRESS RELEASE published on 05/06/2024 at 12:30, 2 years ago Immunic to Participate in Investor and Scientific Conferences in May Immunic, Inc. to participate in investor and scientific conferences in May, presenting clinical trial data on oral therapies for inflammatory diseases Investor Conferences Clinical Trials Immunic Inc. Inflammatory Diseases Scientific Conferences
Published on 05/09/2026 at 01:30, 1 day 15 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 16 hours ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/10/2026 at 16:05, 24 minutes ago RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 2 hours 29 minutes ago MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 4 hours 44 minutes ago Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 21 hours 24 minutes ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 19 hours ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/07/2026 at 19:15, 2 days 21 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 21 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 21 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 21 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 21 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
